Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel with or without GSK1120212 for advanced melanoma
ISRCTN43327231Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of trametinib and paclitaxel in melanoma (5 arms), sponsored by University of Oxford. Primary endpoints: Efficacy of GSK1120212 in combination with paclitaxel compared to paclitaxel alone and Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
trametinibpaclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on ISRCTN43327231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43327231.